BrainLAB, a worldwide leading innovator in image-guided medical technology, and Varian Medical Systems, extended their global supply and distribute agreement for the Novalis and m3 products. The agreement extends through 2010, reflecting the strong commitment by both companies to bring the most advanced solutions in cancer therapy to clinicians and patients.
Novalis, the software driven neurosurgery technology, is able to treat both benign and malignant tumours, AVMs and functional disorders with single or multi-fractionation and IMRT. Novalis systems are used to treat thousands of patients each year, for a wide range of indications including cancers of the brain, head and neck, spine, liver, lung and prostate. BrainLAB's continuous focus on software innovation and strong partnerships with industry leaders, such as Varian Medical Systems, keeps Novalis at the forefront of technology, states a company release.
"Novalis systems are used to treat thousands of patients around the world each year, for a wide range of indications including cranial, lung, liver, and spine cancer. Our continuous focus on software innovation and strong partnerships with industry leaders, such as Varian Medical Systems, keeps Novalis at the forefront of technology. This partnership agreement is great news for our clinicians who know and trust that both companies are committed to design, build and sell the best radiosurgery and radiotherapy products and services," said Stefan Vilsmeier, CEO and founder of BrainLAB.
"From the inception of the Novalis technology, we have enjoyed a strong and ongoing partnership with BrainLAB, wherein Varian Medical Systems' linear accelerator and multi-leaf collimator technology play critical roles in a system designed for advanced radiosurgical treatments," said Timothy Guertin, president and chief operating officer of Varian Medical Systems. "We are pleased to continue supporting BrainLAB in its effort to provide hospitals with robust clinical solutions for their patients."
BrainLAB, a privately held company headquartered in Munich, Germany, was founded in 1989 and is specialised in the development, manufacture, and marketing of medical technology for radiosurgery, orthopaedics, neurosurgery, and ENT.